Zydus Lifesciences Limited
ZYDUSLIFE
Rank in Stocks
#1750
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952,... Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Share Price
$12.30
Market Cap
$12.27B
Change (1 day)
0.06%
Change (1 year)
8.33%
Country
IN
Trade Zydus Lifesciences Limited (ZYDUSLIFE)
Category
Healthcare
P/B ratio for Zydus Lifesciences Limited (ZYDUSLIFE)
P/B ratio as of October 2026 TTM: 3.84
According to Zydus Lifesciences Limited latest financial reports and stock price the company's current price-to-book ratio (TTM) is 3.84. At the end of 2024 the company had a P/B ratio of 5.10.
P/B ratio history for Zydus Lifesciences Limited from 2004 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| 2026 (TTM) | 3.84 | 4.02% |
| 2025 | 3.69 | -27.74% |
| 2024 | 5.10 | 79.01% |
| 2023 | 2.85 | 35.81% |
| 2022 | 2.10 | -39.59% |
| 2021 | 3.47 | 31.75% |
| 2020 | 2.64 | -22.29% |
| 2019 | 3.39 | -24.73% |
| 2018 | 4.51 | -30.66% |
| 2017 | 6.50 | 7.25% |
| 2016 | 6.06 | -27.73% |
| 2015 | 8.39 | 37.46% |
| 2014 | 6.10 | 19.12% |
| 2013 | 5.12 | -15.11% |
| 2012 | 6.03 | -18.98% |
| 2011 | 7.45 | 7.23% |
| 2010 | 6.95 | 131.38% |
| 2009 | 3.00 | 7.99% |
| 2008 | 2.78 | -38.66% |
| 2007 | 4.53 | -59.76% |
| 2006 | 11.26 | 23.48% |
| 2005 | 9.12 | -53.76% |
| 2004 | 19.72 | 0.00% |
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | 31.33% |
IN
|
